Lab Data Integrity and Data Quality - Part 1

12/13 November 2024, Barcelona, Spain

Course No. 21480



Dr. Christopher Burgess

Dr. Christopher Burgess

Burgess Analytical Consultancy

Dr. Bob McDowall

Dr. Bob McDowall

R.D. McDowall Ltd.


These two courses have the following objectives:

Part 1:
The learning objectives are firstly, understand the data integrity requirements of a GMP regulated laboratory in Pharmaceutical organisations and contract labs from sampling to reporting.  Secondly, how laboratory personnel can ensure compliance and be able to defend their positions. Records generated by three processes will be taken through the presentations and workshops: paper only with records maintained in a laboratory notebook or controlled sheets, hybrid system with signed paper records with underlying electronic records and an electronic system using electronic signatures. Second person review is a critical process that needs to be thorough and effective to ensure that data issues are picked up and resolved.

Part 2:
The auditing course will develop the understanding of what is required for a data integrity audit of a laboratory computerized system and then develop the principles, based mainly on workshops and discussions, of how to audit hybrid and electronic laboratory systems. The scope of auditing a system for data integrity will be developed during the course along with a risk based prioritisation of the key areas to focus audit attention on. In preparation for the final sessions there will be workshops dealing with specific data integrity topics. At the end, attendees will read the laboratory audit report, determine if there are any findings and classify them. Then feedback selected audit findings to the Quality Control manager and head of Quality Assurance.

A checklist will be provided to all attendees for the auditing of computerised systems for data Integrity.


Data Integrity continues to be the major concern with both FDA and European Regulatory Agencies. Many FDA warning letters and EU GMP inspections have highlighted major data integrity failures at companies globally. The regulatory concern has been responded by FDA issuing three versions of Compliance Program Guide (CPG) 7346.832 that covers Pre-Approval Inspections in 2010, 2019 and 2022. The latest version extends the objectives to include Quality in Pharmaceutical Development. Since 2015, various regulatory authorities have published data integrity guidance documents e.g.
  • MHRA: 2 versions of a GMP guidance in 2015 and a GXP guidance in 2018
  • WHO: two guidance documents in 2016 and 2021.  The 2016 version is more comprehensive and contains the best description of ALCOA criteria in any regulatory guidance.
  • FDA: issued an interpretation of CGMP about data integrity in a Q&A format in 2018
  • PIC/S: published their final version of PI-041 guidance in 2021 and FDA: issued a draft guidance for Remote Interactive Investigations in 2023
Moreover, EU GMP Annex 11 for computerised systems and Chapter 4 on documentation are being updated to enhance the requirements for data Integrity. Industry bodies have also been active with the GAMP Forum publishing a Records and Data Integrity Guide in 2017 and three Good Practice Guides.  APIC and PDA have issued guidance documents on the subject.

Finally, ECA have issued the 3rd Edition of a Data Governance and Data Integrity Guide that delegates will get a free electronic copy of.

The emphasis of all regulators is on the ALCOA++ principles to outline regulatory expectations for ways to ensure the integrity of data over the life cycle. This is reflected in the way the two courses will be presented.

Part 1 focuses on three types of record that can be found in analytical laboratories working to GMP: paper, hybrid computerized system and electronic workflows with electronic signatures. Through presentations, work- shops and discussions attendees are taken through the process from sampling to generation of the reportable value to understand data integrity issues.

Part 2 takes the principles from the earlier course and develops them to enable attendees to be able to conduct effective internal audits or self-inspections of either hybrid or electronic systems in compliance with EU GMP Chapter 9. This is achieved mainly via a series of interlinked workshops with a few presentations.

Target Group

These courses will be of significant value to:
  • Managers and scientists from quality control and analytical development laboratories wanting to understand the data integrity and audit process
  • Quality assurance personnel
  • Contract research organisation and contract manufacturing organisation, laboratory and QA personnel
  • Auditors (internal and external) responsible for assessing laboratory quality and data integrity

Presentations / Certificate

The presentations for this event will be available for you to download and print before and after the event. Please note that no printed materials will be handed out on site and that there will not be any opportunity to print the presentations on site.

After the event, you will automatically receive your certificate of participation.


Lab Data Integrity and Data Quality - Part 1

Seminar Programme as PDF

Programme Part 1:
Data Governance, Integrity & Quality, Regulations and Guidance
  • Summary of EU and FDA GMP requirements
  • MHRA, PIC/S and WHO Data Integrity Guidances
  • FDA Guidance documents OOS, Inspection of QC labs
  • Inspection findings 483 and warning letters
  • Defining data integrity, “complete data” and „raw data“
Analytical Process Mapping and Where Are the Vulnerabilities
  • Essential to map the process and identify all steps for traceability
  • SOPs, analytical procedures & training of staff
  • Internal and external auditing support
  • Identifying data and the controls to ensure integrity
Assessment of an Analytical Process for Data Integrity Vulnerabilities of a Pharmacopoeial Loss on Drying Assay

Presented with a pharmacopoeial Loss on Drying (LOD) analysis attendees identify any data vulnerabilities in the process

Role of Sampling in Ensuring Data Integrity
  • Why is proper sampling the key to ensuring the integrity and reliability of analysis?
  • What are the key features of sampling?
Principles for the Generation of Data
  • Qualified analytical instruments and validated Software
  • Recording observational tests and instrument/system tests
  • Identification of key vunerabilities
  • Application of ALCOA++ principles
Generation of Data
  • What are the requirements for raw data integrity?
  • Three scenarios covering:
    • a paper System
    • a hybrid System
    • a networked electronic System
Processing and Reporting of Data
  • Paper / hybrid based systems
  • Networked systems with electronic records and signatures
  • Calculations and transformation of data manually and by computer applications
  • Application of ALCOA++ principles to the process
  • Calculating the reportable value and comparison with the specification
  • Paper processes versus electronic processes
  • Linkage with out of specification investigations (OOS)
Processing and Reporting of Data
  • Reviewing an analytical record
  • Scenario covering paper based record and an electronic system
Reviewing Data and Collating Records
  • Identification and correction of errors for paper and electronic systems
  • Do you have complete data?
WORKSHOP IV and facilitated Discussion: Reviewing analytical records; Do we have to check everything?
Using technical controls to aid the Reviewer

Data Review of an Excel Template

Application of ALCOA+ principles for the review of paper records

Second Person Review including Audit Trail Review
  • Role of the second person review
  • Determination that the reportable result is correctly calculated
  • Identification and correction of errors for paper and electronic systems
  • Facilitated Discussion: Reviewing audit trails by exception
Facilitated Discussion
  • Paper, Hybrid and Electronic Reporting Processes
  • Discussion of the strengths and weaknesses of reporting processes
Key Learning Points and Final Discussion
End of Part 1 / Registration for Part 2


This course is part of the GMP Certification Programme "ECA Certified Data Integrity Manager" Learn more

ECA-Member*: € 1290,-
Non ECA Member*: € 1490,-
EU/GMP Inspectorates*: € 745,-
APIC Member Discount*: € 1390,-

(All prices excl. VAT). Important notes on sales tax.

* also payable by credit card
American Express Visa Mastercard

Further dates on-site
Further dates on-site
Not available
Further dates online
Further dates online
Not available
Not available

Do you have any questions?

Please contact us:
Tel.: +49 6221 8444-0

Woman with headset

Go back

Testimonials about our courses and conferences

“Fantastic course – I really enjoyed the interactive structure & greatly appreciate social activity.”

Anthony Cummins, Sebela Pharmaceuticals, Ireland
GMP Auditor Practice, September 2023


“Very well organized, information on point without being overwhelming.”

Eleni Kallinikou, Pharmathen
Live Online Trainng - Pharmaceutical Contracts - Febuary 2024


“Good overview of different types of agreements, good to see both the GMP and the legal angle”

Ann Michiels, Johnson&Johnson
Live Online Trainng - Pharmaceutical Contracts, Febuary 2024



“Well prepared presentations and good presenters. I also like the way of asking questions.”

Alexandra Weidler, Hookipa Biotech GmbH, Austria
Live Online Training – QP Education Course Module A, November 2023